[P02BB01, trichlorfon, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Metrifonate.]
[S02DA03, antipyrine, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Streptokinase.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Paroxetine.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Sulindac.]
[N05AL01, sulpiride, Paroxetine may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sulthiame is combined with Paroxetine.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Azapropazone.]
[N06DA01, tacrine, The metabolism of Paroxetine can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The therapeutic efficacy of Tamoxifen can be decreased when used in combination with Paroxetine.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Paroxetine.]
[L01CB02, teniposide, The metabolism of Paroxetine can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Terbutaline.]
[B01AE07, dabigatran etexilate, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Paroxetine can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Paroxetine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Tetracaine is combined with Paroxetine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lurasidone is combined with Paroxetine.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Paroxetine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Paroxetine.]
[L04AX02, thalidomide, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Paroxetine.]
[R03DA04, theophylline, The serum concentration of Theophylline can be increased when it is combined with Paroxetine.]
[P02CA02, thiabendazole, The metabolism of Paroxetine can be decreased when combined with Thiabendazole.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Paroxetine.]
[L01AC01, thiotepa, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Paroxetine.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Paroxetine.]
[N05AC02, thioridazine, Paroxetine may increase the QTc-prolonging activities of Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Paroxetine.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Paroxetine.]
[B02AB01, aprotinin, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Aprotinin.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Paroxetine.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Paroxetine.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Tiapride is combined with Paroxetine.]
[B01AC05, ticlopidine, The metabolism of Paroxetine can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of serotonin syndrome can be increased when Tilidine is combined with Paroxetine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Paroxetine.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Tolazamide.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tolperisone is combined with Paroxetine.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the serotonergic activities of Paroxetine.]
[C01DX11, trapidil, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Trapidil.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Paroxetine.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Paroxetine.]
[C03DB02, triamterene, The metabolism of Paroxetine can be decreased when combined with Triamterene.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Paroxetine.]
[C03AA06, trichlormethiazide, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paroxetine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Trifluperidol is combined with Paroxetine.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Paroxetine.]
[N04AA01, trihexyphenidyl, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Paroxetine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Paroxetine.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Paroxetine is combined with Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Paroxetine.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Paroxetine.]
[R06AC04, tripelennamine, The metabolism of Paroxetine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Paroxetine.]
[A03BB01, butylscopolamine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Paroxetine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Paroxetine can be decreased when combined with Vilazodone.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Paroxetine is combined with Tropicamide.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Paroxetine is combined with Tryptophan.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Paroxetine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Paroxetine.]
[S01AA05, tyrothricin, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Tyrothricin.]
[L02BX03, abiraterone, The serum concentration of Paroxetine can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Paroxetine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Paroxetine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be increased when it is combined with Paroxetine.]
[B01AD04, urokinase, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Urokinase.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ezogabine is combined with Paroxetine.]
[B01AF01, rivaroxaban, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Paroxetine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Paroxetine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Paroxetine can be decreased when combined with Vinblastine.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Paroxetine is combined with Warfarin.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Paroxetine.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Paroxetine.]
[J05AE02, indinavir, The metabolism of Paroxetine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Paroxetine.]
[L01EC01, vemurafenib, The serum concentration of Paroxetine can be increased when it is combined with Vemurafenib.]
[L01ED01, crizotinib, The metabolism of Paroxetine can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Paroxetine can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Paroxetine can be decreased when combined with Rabeprazole.]
[J01MA13, trovafloxacin, The metabolism of Paroxetine can be decreased when combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Paroxetine is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Paroxetine.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Paroxetine.]
[C07AB03, atenolol, The metabolism of Atenolol can be decreased when combined with Paroxetine.]
[L03AB11, peginterferon alfa-2a, The metabolism of Paroxetine can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The metabolism of Paroxetine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Paroxetine.]
[S01FA01, atropine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Paroxetine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Paroxetine.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Paroxetine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Paroxetine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.]
[A08AA11, lorcaserin, The metabolism of Paroxetine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Paroxetine is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Paroxetine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Paroxetine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Paroxetine can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Paroxetine.]
[L04AA31, teriflunomide, The serum concentration of Paroxetine can be decreased when it is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Defibrotide.]
[C01CA18, octopamine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Octopamine.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Paroxetine.]
[J05AE04, nelfinavir, The metabolism of Paroxetine can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Paroxetine.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.]
[N04BD02, rasagiline, Rasagiline may increase the serotonergic activities of Paroxetine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Mosapride is combined with Paroxetine.]
[N06DA02, donepezil, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Paroxetine.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Paroxetine can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Diethyl ether is combined with Paroxetine.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Paroxetine.]
[H01CB05, pasireotide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Paroxetine.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Paroxetine.]
[B01AF02, apixaban, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Apixaban.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Paroxetine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Paroxetine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Paroxetine.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Paroxetine.]
[N02BA10, benorilate, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Benperidol is combined with Paroxetine.]
[A10BK02, canagliflozin, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The metabolism of Paroxetine can be decreased when combined with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Paroxetine can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The metabolism of Paroxetine can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Paroxetine can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Paroxetine.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin detemir.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Paroxetine.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Paroxetine.]
[M01AH01, celecoxib, The risk or severity of bleeding can be increased when Celecoxib is combined with Paroxetine.]
[N02CC02, naratriptan, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Paroxetine can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The metabolism of Benzatropine can be decreased when combined with Paroxetine.]
[L01EC02, dabrafenib, The serum concentration of Paroxetine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Paroxetine.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Paroxetine.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Paroxetine.]
[C08EA02, bepridil, The metabolism of Bepridil can be decreased when combined with Paroxetine.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Lixisenatide.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Paroxetine.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Paroxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Paroxetine.]
[D01AC18, luliconazole, The serum concentration of Paroxetine can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The metabolism of Paroxetine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Paroxetine.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Paroxetine.]
[C01CA27, droxidopa, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Droxidopa.]
[C07AB04, acebutolol, The metabolism of Acebutolol can be decreased when combined with Paroxetine.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Tasimelteon is combined with Paroxetine.]
[A16AA07, metreleptin, The metabolism of Paroxetine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Paroxetine can be increased when combined with Apremilast.]
[A16AA06, betaine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Betaine.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Paroxetine.]
[B01AE03, argatroban, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Argatroban.]
[C02CC01, bethanidine, The risk or severity of Tachycardia can be increased when Bethanidine is combined with Paroxetine.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Paroxetine can be increased when combined with Siltuximab.]
[B01AC26, vorapaxar, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Vorapaxar.]
[A03BA03, hyoscyamine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Paroxetine.]
[L01XH04, belinostat, The metabolism of Paroxetine can be increased when combined with Belinostat.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Alfaxalone is combined with Paroxetine.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Empagliflozin.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Paroxetine.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Paroxetine is combined with Glycopyrronium.]
[N05CM19, suvorexant, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Paroxetine.]
[J01XA05, oritavancin, The metabolism of Paroxetine can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Paroxetine.]
[V04CX03, methacholine, Paroxetine may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Paroxetine.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Dulaglutide.]
[A06AH03, naloxegol, The risk or severity of serotonin syndrome can be increased when Naloxegol is combined with Paroxetine.]
[N04AA02, biperiden, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Paroxetine.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Paroxetine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Paroxetine.]
[B01AA01, dicumarol, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Edoxaban.]
[N06AX11, mirtazapine, Paroxetine may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Paroxetine can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Paroxetine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Paroxetine.]
[A03AA09, difemerine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Tioclomarol.]
[J05AP06, asunaprevir, The metabolism of Paroxetine can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Paroxetine is combined with Eluxadoline.]
[B01AC25, cangrelor, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Cangrelor.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Paroxetine.]
[A04AD14, rolapitant, The metabolism of Paroxetine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Flibanserin is combined with Paroxetine.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Paroxetine.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Paroxetine.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Paroxetine.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin degludec.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Paroxetine.]
[A02BC03, lansoprazole, The metabolism of Paroxetine can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Paroxetine.]
[J02AC05, isavuconazole, The metabolism of Paroxetine can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Paroxetine can be decreased when it is combined with Osimertinib.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Acetohexamide.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Paroxetine.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Paroxetine.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Paroxetine.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Paroxetine.]
[L01XX52, venetoclax, The metabolism of Paroxetine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Paroxetine.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Paroxetine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Paroxetine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Paroxetine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Paroxetine.]
[A05AA04, obeticholic acid, The metabolism of Paroxetine can be decreased when combined with Obeticholic acid.]
[N01BB01, bupivacaine, The metabolism of Bupivacaine can be decreased when combined with Paroxetine.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be decreased when combined with Paroxetine.]
[N07BC01, buprenorphine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Paroxetine.]
[N06DA03, rivastigmine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Rivastigmine.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Paroxetine.]
[M02AA03, clofezone, The metabolism of Paroxetine can be decreased when combined with Rabeprazole.]
[N02AF01, butorphanol, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Paroxetine.]
[S01GX07, azelastine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Paroxetine can be decreased when combined with Rucaparib.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Paroxetine.]
[L01EF02, ribociclib, The metabolism of Paroxetine can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Bambuterol.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Paroxetine.]
[N07XX16, deutetrabenazine, The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Paroxetine.]
[N02BF02, pregabalin, The therapeutic efficacy of Paroxetine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Beclamide is combined with Paroxetine.]
[N06BC01, caffeine, The metabolism of Paroxetine can be decreased when combined with Caffeine.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Benfluorex.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Paroxetine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Paroxetine.]
[J05AE09, tipranavir, The metabolism of Paroxetine can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Paroxetine.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Paroxetine.]
[L04AB02, infliximab, The metabolism of Paroxetine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Paroxetine can be decreased when combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Paroxetine.]
[N04BD03, safinamide, Safinamide may increase the serotonergic activities of Paroxetine.]
[B01AF04, betrixaban, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Betrixaban.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Paroxetine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Paroxetine.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Paroxetine.]
[R03AC17, bitolterol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Bitolterol.]
[J05AG03, efavirenz, The metabolism of Paroxetine can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Paroxetine.]
[N04AA11, bornaprine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Bromperidol is combined with Paroxetine.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Brotizolam is combined with Paroxetine.]
[C04AX20, buflomedil, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Paroxetine.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Paroxetine.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Butriptyline is combined with Paroxetine.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Semaglutide.]
[N01BX04, capsaicin, The metabolism of Paroxetine can be increased when combined with Capsaicin.]
[A10BK04, ertugliflozin, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Vinylbital is combined with Paroxetine.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Paroxetine.]
[L02BB05, apalutamide, The serum concentration of Paroxetine can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Paroxetine can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Paroxetine.]
[A03AA03, camylofine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Paroxetine.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Paroxetine.]
[L03AB06, interferon alfa-n1, The metabolism of Paroxetine can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Paroxetine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Paroxetine.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Paroxetine.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Paroxetine.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be decreased when combined with Paroxetine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Paroxetine.]
[L01XX62, ivosidenib, The metabolism of Paroxetine can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Paroxetine.]
[N03AX17, stiripentol, The metabolism of Paroxetine can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Paroxetine can be decreased when combined with Tecovirimat.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Paroxetine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Paroxetine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Carbromal is combined with Paroxetine.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Carbutamide.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Paroxetine.]
[R06AA06, chlorphenoxamine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Paroxetine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Paroxetine.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Paroxetine.]
[L04AA39, emapalumab, The metabolism of Paroxetine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Paroxetine can be decreased when combined with Carmustine.]
[L01EX13, gilteritinib, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Gilteritinib.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Paroxetine.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Cibenzoline.]
[B01AX07, caplacizumab, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Caplacizumab.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Paroxetine.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cinitapride is combined with Paroxetine.]
[P02BX04, triclabendazole, The metabolism of Paroxetine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Paroxetine is combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Paroxetine.]
[J01FA09, clarithromycin, The metabolism of Paroxetine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Paroxetine.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Brexanolone is combined with Paroxetine.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Paroxetine.]
[N05BA09, clobazam, The metabolism of Paroxetine can be decreased when combined with Clobazam.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Paroxetine.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Paroxetine.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Ubidecarenone.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Paroxetine.]
[L04AB01, etanercept, The metabolism of Paroxetine can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The metabolism of Paroxetine can be decreased when combined with Alpelisib.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Cyamemazine is combined with Paroxetine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Paroxetine.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Paroxetine.]
[N07XX11, pitolisant, The serum concentration of Pitolisant can be increased when it is combined with Paroxetine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Paroxetine.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Paroxetine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin pork.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Paroxetine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Paroxetine.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Paroxetine.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be decreased when combined with Paroxetine.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Paroxetine.]
[N03AX25, cenobamate, The serum concentration of Paroxetine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Paroxetine can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Paroxetine.]
[N02AX03, dezocine, The risk or severity of serotonin syndrome can be increased when Dezocine is combined with Paroxetine.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Paroxetine.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Paroxetine.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Paroxetine.]
[M01AX21, diacetylrhein, The metabolism of Paroxetine can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The metabolism of Paroxetine can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Paroxetine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of Paroxetine can be decreased when it is combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Paroxetine.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Paroxetine.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Paroxetine.]
[N02AA08, dihydrocodeine, The risk or severity of serotonin syndrome can be increased when Dihydrocodeine is combined with Paroxetine.]
[N02CC06, eletriptan, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Eletriptan.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be decreased when combined with Paroxetine.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Paroxetine.]
[C01BD07, dronedarone, The metabolism of Paroxetine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Paroxetine.]
[S03AA08, chloramphenicol, The metabolism of Paroxetine can be decreased when combined with Chloramphenicol.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paroxetine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Paroxetine.]
[A03AA08, dihexyverine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be increased when it is combined with Paroxetine.]
[C01CA14, dopexamine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Dopexamine.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Paroxetine.]
[G04BD09, trospium, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Droxicam.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be increased when it is combined with Paroxetine.]
[B01AE02, lepirudin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Clomethiazole is combined with Paroxetine.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Paroxetine.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Paroxetine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Paroxetine.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Paroxetine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Remimazolam is combined with Paroxetine.]
[L04AC19, satralizumab, The serum concentration of Paroxetine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Paroxetine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Paroxetine can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Paroxetine.]
[N05AA01, chlorpromazine, The metabolism of Paroxetine can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Paroxetine.]
[C03BA04, chlorthalidone, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Chlorthalidone.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Paroxetine.]
[A11CC05, cholecalciferol, The metabolism of Paroxetine can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Etifoxine is combined with Paroxetine.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Vinpocetine is combined with Paroxetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Paroxetine.]
[M01AB08, etodolac, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Paroxetine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Lonafarnib can be increased when it is combined with Paroxetine.]
[P03AX07, abametapir, The serum concentration of Paroxetine can be increased when it is combined with Abametapir.]
[V03AF12, trilaciclib, The metabolism of Paroxetine can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Febarbamate is combined with Paroxetine.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Paroxetine.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Fenbufen.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Paroxetine.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Fenozolone.]
[J01MB07, flumequine, The metabolism of Paroxetine can be decreased when combined with Flumequine.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Paroxetine.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin human.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Paroxetine.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Paroxetine can be increased when it is combined with Peginterferon alfa-2b.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Paroxetine.]
[A02BA01, cimetidine, The serum concentration of Paroxetine can be increased when it is combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Paroxetine.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Paroxetine.]
[J01MB06, cinoxacin, The metabolism of Paroxetine can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Paroxetine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Paroxetine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, The metabolism of Citalopram can be decreased when combined with Paroxetine.]
[H01AC07, somapacitan, The metabolism of Paroxetine can be decreased when combined with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Paroxetine.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Paroxetine.]
[L01XX74, belzutifan, The metabolism of Belzutifan can be decreased when combined with Paroxetine.]
[H01AC09, lonapegsomatropin, The metabolism of Paroxetine can be increased when combined with Lonapegsomatropin.]
[V09AB03, ioflupane I-123, Paroxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Paroxetine.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Gliquidone.]
[R03CC13, clenbuterol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Clenbuterol.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Paroxetine.]
[N06AX25, St. John's wort extract, The metabolism of Paroxetine can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Paroxetine can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Paroxetine.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Paroxetine.]
[B01AD11, tenecteplase, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Tenecteplase.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Paroxetine.]
[L01EJ03, pacritinib, The metabolism of Paroxetine can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Paroxetine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Paroxetine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Paroxetine.]
[C01EB24, mavacamten, The serum concentration of Paroxetine can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Tirzepatide.]
[A02BC08, vonoprazan, The metabolism of Paroxetine can be decreased when combined with Vonoprazan.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Clothiapine is combined with Paroxetine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Paroxetine.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Paroxetine.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Paroxetine.]
[N05AH02, clozapine, The metabolism of Paroxetine can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Sotagliflozin.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Paroxetine.]
[H01AC08, somatrogon, The metabolism of Paroxetine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Paroxetine.]
[L04AC21, bimekizumab, The metabolism of Paroxetine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of serotonin syndrome can be increased when Codeine is combined with Paroxetine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Paroxetine.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Paroxetine.]
[A03AB10, hexocyclium, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Paroxetine is combined with Homatropine.]
[A03BB06, homatropine methylbromide, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Paroxetine.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Tropisetron is combined with Paroxetine.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Ifenprodil is combined with Paroxetine.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Paroxetine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Paroxetine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Paroxetine.]
[B01AC10, indobufen, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Paroxetine.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Valdecoxib.]
[H01AX01, pegvisomant, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Pegvisomant.]
[A03AX10, isometheptene, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Paroxetine can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Bemiparin.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be decreased when combined with Paroxetine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Paroxetine.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Paroxetine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Paroxetine can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Paroxetine can be decreased when combined with Esomeprazole.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Paroxetine.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Lamotrigine is combined with Paroxetine.]
[S01GX02, levocabastine, The risk or severity of adverse effects can be increased when Levocabastine is combined with Paroxetine.]
[N07BC04, lofexidine, The therapeutic efficacy of Paroxetine can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The metabolism of Lomefloxacin can be decreased when combined with Paroxetine.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Lonazolac.]
[R06AX13, loratadine, Paroxetine may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Lormetazepam is combined with Paroxetine.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Loxoprofen.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Paroxetine.]
[C08CA11, manidipine, The metabolism of Paroxetine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Medifoxamine is combined with Paroxetine.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Mefenorex.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Paroxetine.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Paroxetine.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Paroxetine.]
[N04AA03, methixene, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Paroxetine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Cyclobarbital is combined with Paroxetine.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Melperone is combined with Paroxetine.]
[C03AA07, cyclopenthiazide, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Cyclopenthiazide.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Miglitol.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Paroxetine is combined with Cyclopentolate.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Paroxetine.]
[N06AX07, minaprine, Minaprine may increase the serotonergic activities of Paroxetine.]
[S01XA18, cyclosporine, The metabolism of Paroxetine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the serotonergic activities of Paroxetine.]
[N06BA07, modafinil, The metabolism of Paroxetine can be decreased when combined with Armodafinil.]
[R06AX02, cyproheptadine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Cyproheptadine.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Paroxetine.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Paroxetine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Moxonidine.]
[J05AF10, entecavir, The metabolism of Paroxetine can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Paroxetine.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Etoricoxib.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Paroxetine.]
[G03XA01, danazol, The metabolism of Paroxetine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Paroxetine.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Deanol is combined with Paroxetine.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Paroxetine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Nabumetone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Nordazepam is combined with Paroxetine.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Paroxetine.]
[N06AX06, nefazodone, The metabolism of Paroxetine can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Niaprazine is combined with Paroxetine.]
[L02BB02, nilutamide, The metabolism of Paroxetine can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Paroxetine.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Paroxetine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Paroxetine.]
[C01CA05, norfenefrine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of serotonin syndrome can be increased when Normethadone is combined with Paroxetine.]
[B01AX05, fondaparinux, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Paroxetine.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Olsalazine.]
[N06AA01, desipramine, The metabolism of Paroxetine can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Desmopressin.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Paroxetine.]
[S03BA01, dexamethasone, The metabolism of Paroxetine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Oxiracetam is combined with Paroxetine.]
[N04AA08, dexetimide, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Paroxetine.]
[A03AA01, oxyphencyclimine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Paroxetine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Paroxetine.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be decreased when combined with Paroxetine.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Paroxetine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Paroxetine.]
[N02AC01, dextromoramide, The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Paroxetine.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Paroxetine.]
[S01AA13, fusidic acid, The metabolism of Paroxetine can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The metabolism of Paroxetine can be decreased when combined with Pipemidic acid.]
[N07XX04, sodium oxybate, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Mefenamic acid.]
[B01AC04, clopidogrel, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of serotonin syndrome can be increased when Diamorphine is combined with Paroxetine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Paroxetine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Paroxetine.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Paroxetine.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Paroxetine.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Dibenzepin is combined with Paroxetine.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Paroxetine.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Diclofenac.]
[A03AA07, dicyclomine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Pipamperone is combined with Paroxetine.]
[A03AB14, pipenzolate, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Paroxetine.]
[R03CC07, pirbuterol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Pirbuterol.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Paroxetine.]
[C08CA03, isradipine, The metabolism of Paroxetine can be decreased when combined with Isradipine.]
[A03AB11, poldine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Diflunisal.]
[C02DB01, dihydralazine, The metabolism of Paroxetine can be decreased when combined with Dihydralazine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paroxetine.]
[N02AA03, hydromorphone, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Paroxetine.]
[J05AE08, atazanavir, The metabolism of Paroxetine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Paroxetine.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Paroxetine.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Pramocaine is combined with Paroxetine.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Paroxetine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Pridinol is combined with Paroxetine.]
[R06AB03, dimethindene, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Paroxetine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Paroxetine.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Paroxetine.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Proglumetacin.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Paroxetine.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Paroxetine.]
[A07DA01, diphenoxylate, The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Paroxetine.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Paroxetine.]
[B01AC07, dipyridamole, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Paroxetine.]
[B01AD10, drotrecogin alfa, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Quinupramine is combined with Paroxetine.]
[A03FA02, cisapride, The metabolism of Paroxetine can be decreased when combined with Cisapride.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be decreased when combined with Paroxetine.]
[R03CC14, reproterol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Reproterol.]
[C01BA03, disopyramide, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07AA03, distigmine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Distigmine.]
[S02AA12, rifamycin SV, The metabolism of Paroxetine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Paroxetine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Paroxetine.]
[N05AX08, risperidone, The serum concentration of Risperidone can be increased when it is combined with Paroxetine.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Levocetirizine is combined with Paroxetine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Paroxetine.]
[J01MB01, rosoxacin, The metabolism of Paroxetine can be decreased when combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Paroxetine can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Paroxetine.]
[J05AE07, fosamprenavir, The serum concentration of Paroxetine can be decreased when it is combined with Fosamprenavir.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Ketorolac.]
[C01EB18, ranolazine, The serum concentration of Paroxetine can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Paroxetine.]
[C01CA07, dobutamine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Paroxetine.]
[C01CA04, dopamine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Dopamine.]
[N06AA16, dothiepin, The metabolism of Paroxetine can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Paroxetine.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Paroxetine.]
[L01DB01, doxorubicin, The metabolism of Paroxetine can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Paroxetine.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Paroxetine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Paroxetine is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Paroxetine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Paroxetine.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Paroxetine.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Sultopride is combined with Paroxetine.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Paroxetine.]
[V04CX07, edrophonium, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Edrophonium.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Paroxetine.]
[J01MA05, temafloxacin, The metabolism of Paroxetine can be decreased when combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Paroxetine can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Paroxetine.]
[S01GA02, tetrahydrozoline, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Tetrazepam is combined with Paroxetine.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Paroxetine.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Thiopropazate is combined with Paroxetine.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Paroxetine.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Tianeptine is combined with Paroxetine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tofisopam is combined with Paroxetine.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the serotonergic activities of Paroxetine.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Paroxetine.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Paroxetine is combined with Topiramate.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Paroxetine.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Tramazoline.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Loprazolam is combined with Paroxetine.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Triclofos is combined with Paroxetine.]
[A03AB08, tridihexethyl, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[B01AC18, triflusal, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Triflusal.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Paroxetine.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Paroxetine.]
[N04AA12, tropatepine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[C05CA04, troxerutin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Troxerutin.]
[R03CC11, tulobuterol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Paroxetine.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Urapidil is combined with Paroxetine.]
[J01MA04, enoxacin, The metabolism of Paroxetine can be decreased when combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Veralipride is combined with Paroxetine.]
[L01CA04, vinorelbine, The metabolism of Paroxetine can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Ephedrine.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Paroxetine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Venlafaxine.]
[C01CX07, xamoterol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Paroxetine can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of Tachycardia can be increased when Epinephrine is combined with Paroxetine.]
[N05CF02, zolpidem, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Paroxetine.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Paroxetine.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Zotepine is combined with Paroxetine.]
[B01AD03, anistreplase, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Anistreplase.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Paroxetine.]
[B01AC11, iloprost, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Paroxetine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Paroxetine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paroxetine.]
[N02CA02, ergotamine, The metabolism of Paroxetine can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Paroxetine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Paroxetine.]
[A02BC02, pantoprazole, The metabolism of Paroxetine can be decreased when combined with Pantoprazole.]
[H05BX01, cinacalcet, The metabolism of Paroxetine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Paroxetine.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Paroxetine can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Paroxetine can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Paroxetine.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paroxetine.]
[L02AA03, ethinyl estradiol, The metabolism of Paroxetine can be decreased when combined with Ethinylestradiol.]
[N04AA05, profenamine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Paroxetine.]
[M01AC06, meloxicam, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Paroxetine.]
[C01CA01, etilefrine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Paroxetine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Paroxetine.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Paroxetine.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Paroxetine.]
[A02BA04, nizatidine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Nizatidine.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Paroxetine.]
[R06AX12, terfenadine, The metabolism of Paroxetine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Paroxetine.]
[N06AB08, fluvoxamine, The metabolism of Paroxetine can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Paroxetine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Paroxetine.]
[C10AA03, pravastatin, The risk or severity of increased glucose can be increased when Pravastatin is combined with Paroxetine.]
[B05AA05, dextran, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Dextran.]
[A02BA03, famotidine, The metabolism of Paroxetine can be decreased when combined with Famotidine.]
[P02CA03, albendazole, The metabolism of Paroxetine can be increased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Paroxetine can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Paroxetine is combined with Fenoterol.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Paroxetine.]
[R03CC02, albuterol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Salbutamol.]
[B01AD05, plasmin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Fibrinolysin.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Paroxetine.]
[G04BD02, flavoxate, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Paroxetine.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Paroxetine can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Paroxetine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Paroxetine.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Melitracen is combined with Paroxetine.]
[V03AZ01, ethanol, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The metabolism of Paroxetine can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The serum concentration of Paroxetine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Paroxetine.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Paroxetine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Paroxetine.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Paroxetine.]
[L02BB01, flutamide, The metabolism of Paroxetine can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Paroxetine.]
[N06BX17, adrafinil, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Paroxetine.]
[G01AX06, furazolidone, Furazolidone may increase the serotonergic activities of Paroxetine.]
[J05AE10, darunavir, The serum concentration of Paroxetine can be decreased when it is combined with Darunavir.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Paroxetine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Amisulpride is combined with Paroxetine.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Paroxetine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Paroxetine.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Barbexaclone is combined with Paroxetine.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Bifemelane is combined with Paroxetine.]
[C10AB04, gemfibrozil, The metabolism of Paroxetine can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Paroxetine.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Paroxetine.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Paroxetine.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Liraglutide.]
[J05AG04, etravirine, The metabolism of Paroxetine can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.]
[N01AH02, alfentanil, The risk or severity of serotonin syndrome can be increased when Alfentanil is combined with Paroxetine.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Paroxetine.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Glipizide.]
[H04AA01, glucagon, Paroxetine may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paroxetine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Paroxetine.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Paroxetine.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Paroxetine.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Paroxetine.]
[L01EX02, sorafenib, The metabolism of Paroxetine can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, The metabolism of Esmolol can be decreased when combined with Paroxetine.]
[B01AA12, fluindione, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Fluindione.]
[P01BX01, halofantrine, The metabolism of Paroxetine can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Paroxetine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Paroxetine.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be decreased when combined with Paroxetine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin aspart.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Iprazochrome is combined with Paroxetine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Paroxetine.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Allobarbital is combined with Paroxetine.]
[C09CA01, losartan, The metabolism of Paroxetine can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Heparin.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Paroxetine.]
[A07EC02, mesalamine, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Mesalazine.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Paroxetine.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Paroxetine.]
[R03CC05, hexoprenaline, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Paroxetine.]
[C08CA10, nilvadipine, The metabolism of Paroxetine can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Nimesulide.]
[C03AA03, hydrochlorothiazide, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Hydroflumethiazide.]
[G04BD06, propiverine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Paroxetine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Prothipendyl is combined with Paroxetine.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.]
[J04AB04, rifabutin, The metabolism of Paroxetine can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Ibuprofen.]
[B05CB02, sodium citrate, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Paroxetine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Paroxetine.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Paroxetine.]
[H01AC02, somatrem, The metabolism of Paroxetine can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Paroxetine.]
[N06AA02, imipramine, The metabolism of Paroxetine can be decreased when combined with Imipramine.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Paroxetine.]
[C03BA11, indapamide, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Indapamide.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Indomethacin.]
[L03AB04, interferon alfa-2a, The metabolism of Paroxetine can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Paroxetine can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Paroxetine is combined with Milnacipran.]
[A03AA30, piperidolate, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Articaine is combined with Paroxetine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Paroxetine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine.]
[R06AE01, buclizine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Paroxetine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Anagrelide.]
[C07AA01, alprenolol, The metabolism of Alprenolol can be decreased when combined with Paroxetine.]
[C03BA02, quinethazone, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Quinethazone.]
[L03AB09, interferon alfacon-1, The metabolism of Paroxetine can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Paroxetine.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Iprindole is combined with Paroxetine.]
[N06AF05, iproniazid, Iproniazid may increase the serotonergic activities of Paroxetine.]
[J05AB13, penciclovir, The metabolism of Paroxetine can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Chlorproethazine is combined with Paroxetine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the serotonergic activities of Paroxetine.]
[R03CC06, isoetharine, The risk or severity of Tachycardia can be increased when Isoetharine is combined with Paroxetine.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Paroxetine.]
[S01EB07, isoflurophate, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Paroxetine.]
[J04AC01, isoniazid, The metabolism of Paroxetine can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Isoprenaline.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Exenatide.]
[C04AA01, isoxsuprine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Isoxsuprine.]
[B01AE06, bivalirudin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Bivalirudin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Paroxetine.]
[H01AC01, somatropin, The metabolism of Paroxetine can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Paroxetine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Paroxetine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Ketanserin is combined with Paroxetine.]
[B01AC22, prasugrel, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Paroxetine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The metabolism of Olanzapine can be decreased when combined with Paroxetine.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Ketoprofen.]
[V03AC03, deferasirox, The serum concentration of Paroxetine can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Paroxetine can be increased when combined with Abatacept.]
[C01CA22, arbutamine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Arbutamine.]
[N04BC09, rotigotine, Paroxetine may increase the sedative activities of Rotigotine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Paroxetine.]
[J01MB02, nalidixic acid, The metabolism of Paroxetine can be decreased when combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Paroxetine.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Amantadine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Paroxetine.]
[N07AA30, ambenonium, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Paroxetine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Paroxetine.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Paroxetine.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be decreased when combined with Paroxetine.]
[N06BA13, armodafinil, The metabolism of Paroxetine can be decreased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Paroxetine.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Paroxetine.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Lofepramine is combined with Paroxetine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Paroxetine.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Paroxetine.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Paroxetine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Paroxetine.]
[L01EG01, temsirolimus, The metabolism of Paroxetine can be decreased when combined with Temsirolimus.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Paroxetine.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Paroxetine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Paroxetine can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Paroxetine can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The metabolism of Maprotiline can be decreased when combined with Paroxetine.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Paroxetine.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Paroxetine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, The metabolism of Meclizine can be decreased when combined with Paroxetine.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Medazepam is combined with Paroxetine.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Paroxetine.]
[P01BC02, mefloquine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Dalteparin.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Paroxetine.]
[N06DX01, memantine, The metabolism of Paroxetine can be decreased when combined with Memantine.]
[N02AB02, meperidine, The risk or severity of serotonin syndrome can be increased when Meperidine is combined with Paroxetine.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Mephentermine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Paroxetine.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Paroxetine.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Paroxetine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine.]
[N02AX05, meptazinol, The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Paroxetine.]
[N05AC03, mesoridazine, The metabolism of Mesoridazine can be decreased when combined with Paroxetine.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be decreased when combined with Paroxetine.]
[C01CA09, metaraminol, The risk or severity of Tachycardia can be increased when Metaraminol is combined with Paroxetine.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Metformin.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Paroxetine.]
[H01CB03, lanreotide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Paroxetine.]
[N06BA03, methamphetamine, The metabolism of Metamfetamine can be decreased when combined with Paroxetine.]
[A03AB07, methantheline, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Paroxetine.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Paroxetine.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Paroxetine.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Metergoline is combined with Paroxetine.]
[H03BB02, methimazole, The metabolism of Paroxetine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Paroxetine can be decreased when combined with Pemetrexed.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Paroxetine.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Ziconotide is combined with Paroxetine.]
[N05AA02, methotrimeprazine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Methoxamine.]
[D05BA02, methoxsalen, The metabolism of Paroxetine can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Paroxetine.]
[C03AA08, methyclothiazide, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Methyclothiazide.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Paroxetine.]
[V04CG05, methylene blue, Paroxetine may increase the serotonergic activities of Methylene blue.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Paroxetine.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Paroxetine.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Paroxetine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Paroxetine.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Paroxetine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Paroxetine.]
[C03BA08, metolazone, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Metolazone.]
[C07AB02, metoprolol, The metabolism of Paroxetine can be decreased when combined with Metoprolol.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Paroxetine.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Paroxetine.]
[S02AA13, miconazole, The metabolism of Paroxetine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Paroxetine.]
[C01CA17, midodrine, The risk or severity of Tachycardia can be increased when Midodrine is combined with Paroxetine.]
[G03XB01, mifepristone, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Tinzaparin.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Paroxetine.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Paroxetine.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.]
[L01XX23, mitotane, The metabolism of Paroxetine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be decreased when combined with Paroxetine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Paroxetine.]
[C01BD01, amiodarone, The metabolism of Paroxetine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Paroxetine.]
[N02AA01, morphine, The risk or severity of serotonin syndrome can be increased when Morphine is combined with Paroxetine.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Paroxetine.]
[L04AB05, certolizumab pegol, The metabolism of Paroxetine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Paroxetine.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Paroxetine.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Paroxetine.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Paroxetine.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Paroxetine.]
[N03AB05, fosphenytoin, The serum concentration of Paroxetine can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Paroxetine can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Paroxetine.]
[N04BC04, ropinirole, Paroxetine may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The metabolism of Paroxetine can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Paroxetine.]
[N02AF02, nalbuphine, The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Paroxetine.]
[V03AB15, naloxone, The metabolism of Paroxetine can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Paroxetine.]
[L04AC03, anakinra, The metabolism of Paroxetine can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Naphazoline.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be decreased when combined with Paroxetine.]
[M02AA12, naproxen, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Naproxen.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Paroxetine can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Paroxetine.]
[L02BG04, letrozole, The metabolism of Paroxetine can be decreased when combined with Letrozole.]
[N01AH06, remifentanil, The risk or severity of serotonin syndrome can be increased when Remifentanil is combined with Paroxetine.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Repaglinide.]
[B01AC17, tirofiban, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Tirofiban.]
[S01EB06, neostigmine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Paroxetine.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Paroxetine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Paroxetine can be decreased when combined with Telmisartan.]
[C10AD02, niacin, The metabolism of Paroxetine can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the serotonergic activities of Paroxetine.]
[C08CA04, nicardipine, The metabolism of Paroxetine can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Paroxetine.]
[P02DA01, niclosamide, The metabolism of Paroxetine can be decreased when combined with Niclosamide.]
[N07BA01, nicotine, The metabolism of Nicotine can be decreased when combined with Paroxetine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Paroxetine.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Niflumic acid.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Paroxetine.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Paroxetine.]
[N04BC05, pramipexole, Paroxetine may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Paroxetine.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Paroxetine.]
[C01CA03, norepinephrine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Paroxetine.]
[S01AE02, norfloxacin, The metabolism of Paroxetine can be decreased when combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Bosentan can be decreased when combined with Paroxetine.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Paroxetine.]
[B01AC16, eptifibatide, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Eptifibatide.]
[L03AB07, interferon beta-1a, The metabolism of Paroxetine can be decreased when combined with Interferon beta-1a.]
[G02CA02, nylidrin, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Nylidrin.]
[B01AB08, reviparin, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Reviparin.]
[H01CB02, octreotide, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Paroxetine.]
[L04AC04, rilonacept, The metabolism of Paroxetine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Paroxetine can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Opipramol is combined with Paroxetine.]
[N02AA02, opium, The risk or severity of serotonin syndrome can be increased when Opium is combined with Paroxetine.]
[R03CB03, metaproterenol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Orciprenaline.]
[B01AD07, reteplase, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Ancrod.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Paroxetine.]
[P02BA02, oxamniquine, The metabolism of Paroxetine can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Paroxetine.]
[C07AA02, oxprenolol, The metabolism of Oxprenolol can be decreased when combined with Paroxetine.]
[N02AA05, oxycodone, The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Paroxetine.]
[C01DX03, oxyfedrine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Paroxetine.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Oxypertine is combined with Paroxetine.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Asenapine is combined with Paroxetine.]
[B01AB09, danaparoid, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Paroxetine.]
[N05CC05, paraldehyde, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the serotonergic activities of Paroxetine.]
[J01MA03, pefloxacin, The metabolism of Paroxetine can be decreased when combined with Pefloxacin.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Paroxetine.]
[C07AA23, penbutolol, The metabolism of Penbutolol can be decreased when combined with Paroxetine.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Penfluridol is combined with Paroxetine.]
[N02AD01, pentazocine, The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Paroxetine.]
[N05CA01, pentobarbital, The metabolism of Paroxetine can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Perazine is combined with Paroxetine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Paroxetine.]
[C08EX02, perhexiline, The metabolism of Paroxetine can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Paroxetine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Paroxetine.]
[N02AD02, phenazocine, The risk or severity of serotonin syndrome can be increased when Phenazocine is combined with Paroxetine.]
[N06AF03, phenelzine, Phenelzine may increase the serotonergic activities of Paroxetine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Paroxetine.]
[B01AA02, phenindione, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Paroxetine.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Paroxetine.]
[N01AH04, phenoperidine, The risk or severity of serotonin syndrome can be increased when Phenoperidine is combined with Paroxetine.]
[B01AA04, phenprocoumon, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Paroxetine.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The metabolism of Paroxetine can be increased when combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Paroxetine can be decreased when combined with Dexlansoprazole.]
[R01BA01, phenylpropanolamine, The risk or severity of Tachycardia can be increased when Phenylpropanolamine is combined with Paroxetine.]
[N03AB02, phenytoin, The serum concentration of Paroxetine can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Paroxetine can be increased when combined with Golimumab.]
[V03AB19, physostigmine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Physostigmine.]
[C08CX01, mibefradil, The metabolism of Paroxetine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Paroxetine is combined with Pimozide.]
[C07AA03, pindolol, The metabolism of Pindolol can be decreased when combined with Paroxetine.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Paroxetine.]
[J05AE01, saquinavir, The metabolism of Paroxetine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Paroxetine.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Paroxetine.]
[A02BX03, pirenzepine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of serotonin syndrome can be increased when Piritramide is combined with Paroxetine.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Piroxicam.]
[J01MA11, grepafloxacin, The metabolism of Paroxetine can be decreased when combined with Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Paroxetine.]
[J05AG02, delavirdine, The metabolism of Paroxetine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Paroxetine.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Proxibarbal is combined with Paroxetine.]
[B01AC13, abciximab, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Alteplase.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Rosiglitazone.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Paroxetine.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Paroxetine.]
[L04AC08, canakinumab, The metabolism of Paroxetine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of hyponatremia can be increased when Paroxetine is combined with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Paroxetine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Saxagliptin.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Paroxetine is combined with Potassium chloride.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Paroxetine.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin lispro.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Paroxetine.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Paroxetine.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Paroxetine.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Paroxetine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Paroxetine.]
[P01BA03, primaquine, The metabolism of Paroxetine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Paroxetine can be increased when combined with Primidone.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Paroxetine.]
[S01HA05, procaine, Procaine may increase the serotonergic activities of Paroxetine.]
[L01XB01, procarbazine, Procarbazine may increase the serotonergic activities of Paroxetine.]
[C10AB05, fenofibrate, The metabolism of Paroxetine can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be decreased when combined with Paroxetine.]
[N04AA04, procyclidine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Paroxetine.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Paroxetine.]
[R06AD02, promethazine, The metabolism of Promethazine can be decreased when combined with Paroxetine.]
[C01BC03, propafenone, The metabolism of Propafenone can be decreased when combined with Paroxetine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Propanidid is combined with Paroxetine.]
[A03AB05, propantheline, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Paroxetine.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Paroxetine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Paroxetine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Paroxetine.]
[N02AC04, propoxyphene, The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Paroxetine.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Paroxetine.]
[N02CC04, rizatriptan, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Rizatriptan.]
[B01AC09, epoprostenol, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Paroxetine.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Paroxetine.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Paroxetine.]
[A03AB15, diphemanil, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Paroxetine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Vinbarbital is combined with Paroxetine.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Captodiame is combined with Paroxetine.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Styramate is combined with Paroxetine.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Pyrantel is combined with Paroxetine.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Mepyramine is combined with Paroxetine.]
[C01BA01, quinidine, The metabolism of Paroxetine can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Paroxetine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Paroxetine can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Paroxetine.]
[J04AB02, rifampin, The metabolism of Paroxetine can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Paroxetine.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Paroxetine.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Paroxetine.]
[N04BD01, selegiline, Selegiline may increase the serotonergic activities of Paroxetine.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Paroxetine.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Paroxetine.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Paroxetine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Paroxetine.]
[H02CA04, levoketoconazole, The metabolism of Paroxetine can be decreased when combined with Levoketoconazole.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Paroxetine is combined with Ipratropium.]
[N06AF04, tranylcypromine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AF01, isocarboxazid, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AF03, phenelzine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[L01XB01, procarbazine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N04BD01, selegiline, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
